Cite this article
Outcomes of concurrent radiotherapy and weekly paclitaxel/carboplatin therapy in cervical cancer: a retrospective study
1 Department of Obstetrics and Gynecology, Jichi Medical University, Saitama, Japan
Eur. J. Gynaecol. Oncol. 2016 , 37(4), 511–516; https://doi.org/10.12892/ejgo3101.2016
Published: 10 August 2016
Purpose of investigation: To determine if concurrent chemoradiotherapy (CCRT) with paclitaxel and carboplatin is effective, convenient, and tolerable for cervical cancer treatment. Materials and Methods: The authors retrospectively reviewed the medical records of 49 patients. Primary outcomes included progression-free survival (PFS) and overall survival (OS). The Cox proportional hazards model was adjusted for all prognostic factors in the multivariable analysis. Results: Over the median follow-up time of 32 months in a sample consisting of 87.8% (43/49) squamous cell carcinoma and 12.2% (6/49) adenocarcinoma, two-year PFS and OS rates were 67.2% and 80.9%, respectively. In univariate analyses, stage, histology, performance status, tumor size, and age were significant variables for OS; only histology was significant in the multivariable analysis. Acute toxicity grade 3 or 4 neutropenia (85.7%), diarrhea (32.7%), and late toxicity grade 3 or 4 (12.2%) were detected. Conclusions: For cervical cancer treatment, CCRT with paclitaxel/carboplatin is satisfactory.
Uterine cervical neoplasms